live attenuated vaccines
Recently Published Documents


TOTAL DOCUMENTS

199
(FIVE YEARS 76)

H-INDEX

30
(FIVE YEARS 5)

2021 ◽  
Vol 57 (4) ◽  
pp. 365
Author(s):  
Yoseph Jeffry Hertanto ◽  
Bernadette Dian Novita

Highlight:Differences in the efficacy of CYD-TDV versus the other TAK-003 and TV003/TV005 were discussed.One licensed dengue vaccine is CYD-TDV (Dengvaxia). Abstract:Dengue fever is the most common tropical disease, but there still remains no specific therapy that can overcome it. Special attention needs to be paid to this disease, because there were large increases in incidence in the last decade. As an effective preventive strategy, finding a new vaccine for dengue fever with higher potentiation and efficacy is highly necessary to stop dengue transmission especially in the endemic area. Vaccine triggers an immune response, so that it can create a robust immune response when infected. Nowadays, there is only one licensed dengue vaccine that is CYD-TDV (Dengvaxia). However, this vaccine still has many weaknesses, namely its dependency on the serostatus of the recipient. There are also other dengue vaccines that are in ongoing clinical testing and have promising results, TDV (TAK-003) and TV003/TV005. These three vaccines are live attenuated vaccines with various results. This review discussed differences in the efficacy of CYD-TDV against the other TAK-003 and TV003/TV005; considering the known and unknown various factors.


mBio ◽  
2021 ◽  
Author(s):  
Paul B. Kilgore ◽  
Jian Sha ◽  
Emily K. Hendrix ◽  
Vladimir L. Motin ◽  
Ashok K. Chopra

Yersinia pestis , the causative agent of plague, is a Tier-1 select agent and a reemerging human pathogen. A 2017 outbreak in Madagascar with >75% of cases being pneumonic and 8.6% causalities emphasized the importance of the disease.


Author(s):  
Jose C. Solana ◽  
Javier Moreno ◽  
Salvador Iborra ◽  
Manuel Soto ◽  
Jose M. Requena

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Tao Wang ◽  
Rui Luo ◽  
Yuan Sun ◽  
Hua-Ji Qiu

Abstract Background African swine fever (ASF) is a fatal hemorrhagic disease in domestic pigs and wild boar caused by African swine fever virus (ASFV). Since ASF has been introduced into Europe and Asia, the major pig-raising areas, posing a huge threat to the pork industry worldwide. Currently, prevention and control of ASF are basically dependent on strict biosecurity measures and stamping-out policy once ASF occurs. Main text The major risks of ASF spread are insufficient biosecurity measures and human behaviors. Therefore, a safe and effective vaccine seems to be a reasonable demand for the prevention and control of ASF. Due to the efficacy advantage over other types of vaccines, live attenuated vaccines (LAVs), especially virulence-associated genes deleted vaccines, are likely to be put into emergency and conditional use in restricted areas if ASF is out of control in a country with a huge pig population and pork consumption, like China. However, the safety, efficacy, and genetic stability of current candidate ASF LAVs require comprehensive clinical evaluations prior to country-wide field application. Several critical issues need to be addressed to commercialize an ideal ASF LAV, including a stable cell line for manufacturing vaccines, differentiation of infected from vaccinated animals (DIVA), and cross-protection from different genotypes. Conclusion A safe and effective DIVA vaccine and an accompanying diagnostic assay will facilitate the prevention, control, and eradication of ASF, which is quite challenging in the near future. Graphical Abstract


2021 ◽  
Vol 8 (1) ◽  
Author(s):  
Xue-Liang Peng ◽  
Ji-Si-Yu Cheng ◽  
Hai-Lun Gong ◽  
Meng-Di Yuan ◽  
Xiao-Hong Zhao ◽  
...  

AbstractSince the end of 2019, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The RNA genome of SARS-CoV-2, which is highly infectious and prone to rapid mutation, encodes both structural and nonstructural proteins. Vaccination is currently the only effective method to prevent COVID-19, and structural proteins are critical targets for vaccine development. Currently, many vaccines are in clinical trials or are already on the market. This review highlights ongoing advances in the design of prophylactic or therapeutic vaccines against COVID-19, including viral vector vaccines, DNA vaccines, RNA vaccines, live-attenuated vaccines, inactivated virus vaccines, recombinant protein vaccines and bionic nanoparticle vaccines. In addition to traditional inactivated virus vaccines, some novel vaccines based on viral vectors, nanoscience and synthetic biology also play important roles in combating COVID-19. However, many challenges persist in ongoing clinical trials.


Author(s):  
Michael E. Wechsler ◽  
Adelmir Souza-Machado ◽  
Christine Xu ◽  
Xuezhou Mao ◽  
Upender Kapoor ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document